An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)

A Dose Ranging Study to Evaluate the Tolerability of MK0524 (Niacin (+) Laropiprant) and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients and/or Normal Healthy Subjects

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00111891

Enrollment

575

Registered

2005-05-27

Start date

2005-06-30

Completion date

2005-08-31

Last updated

2017-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Brief summary

This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.

Detailed description

The duration of treatment is 7 days.

Interventions

DRUGniacin (+) laropiprant

DRUGComparator: placebo (unspecified)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

25 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Males and females (ages 25-75)

Exclusion criteria

* A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study

Design outcomes

Primary

Measure	Time frame
Acute cutaneous symptoms induced by niacin for 7 days.	7 days

Secondary

Measure	Time frame
Tolerability	7 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026